| dbo:abstract
|
- إرتوماكسوماب هو جسم مضاد وحيد النسيلة مجانس (جرذي-فأري) طوّر لعلاج بعض أنواع الأورام. أوقفت التجارب السريرية عليه في مرحلتها الثانية لاستخدامه في علاج سرطان الثدي بعد النتائج التي تحققت في ترازتوزوماب. (ar)
- Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).) (en)
- L'ertumaxomab nome commerciale Rexomun, è un anticorpo monoclonale ibrido Topo/ratto, valutato in studi di fase II per il trattamento del tumore della mammella.Viene anche chiamato anticorpo tri-funzionale perché agisce collegando le cellule T, i macrofagi e le cellule cancerose insieme. Il target molecolare del farmaco è l'antigene HER2/neu e CD3 (it)
|
| dbo:alternativeName
| |
| dbo:casNumber
| |
| dbo:fdaUniiCode
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 2239 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:casNumber
| |
| dbp:chemspiderid
| |
| dbp:mabType
| |
| dbp:source
| |
| dbp:target
| |
| dbp:tradename
| |
| dbp:type
| |
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- إرتوماكسوماب هو جسم مضاد وحيد النسيلة مجانس (جرذي-فأري) طوّر لعلاج بعض أنواع الأورام. أوقفت التجارب السريرية عليه في مرحلتها الثانية لاستخدامه في علاج سرطان الثدي بعد النتائج التي تحققت في ترازتوزوماب. (ar)
- Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer. It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells. Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans. (So they could concentrate on their other product catumaxomab (trade name Removab).) (en)
- L'ertumaxomab nome commerciale Rexomun, è un anticorpo monoclonale ibrido Topo/ratto, valutato in studi di fase II per il trattamento del tumore della mammella.Viene anche chiamato anticorpo tri-funzionale perché agisce collegando le cellule T, i macrofagi e le cellule cancerose insieme. Il target molecolare del farmaco è l'antigene HER2/neu e CD3 (it)
|
| rdfs:label
|
- إرتوماكسوماب (ar)
- Ertumaxomab (en)
- Ertumaxomab (it)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
